Amit Munshi
Presidente en ZURA BIO LIMITED .
Fortuna: 3 M $ al 30/04/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Hans Schambye | M | 59 | 13 años | |
Kimberly Ann Davis | F | 56 | 16 años | |
Robert Lisicki | M | 57 | 5 años | |
Christopher Cabell | M | 54 | 7 años | |
Teofilo Raad | M | 54 |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | 7 años |
Mark Iwicki | M | 57 |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | 7 años |
Steven Schoch | M | 64 | 13 años | |
Jennifer Jarrett | F | 53 | 7 años | |
Richard Batycky | M | 56 |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | 17 años |
Jayson Dallas | M | 56 | 7 años | |
Carl Goldfischer | M | 65 | 4 años | |
Sandeep Kulkarni | M | 43 | 2 años | |
Someit Sidhu | M | 34 | 2 años | |
Matthew Sherman | M | 68 |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | 5 años |
Garrett Winslow | M | 45 | 3 años | |
Laurie Stelzer | F | 56 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 3 años |
Robert Eckert | M | 69 | 21 años | |
Brian Goodman | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Parvinder Thiara | M | 39 | 1 años | |
Michael Howell | M | 47 | 2 años | |
Neil Graham | M | 65 | 1 años | |
Steven Marc Solomon | M | 54 | 3 años | |
Arnout Ploos van Amstel | M | 58 | 1 años | |
Matthew Busch | M | 50 | 20 años | |
Henry Danahay | M | - |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | 9 años |
Martin Gosling | M | - |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | 10 años |
Chau Khuong | M | 48 | 6 años | |
Peter Finan | M | 57 |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | - |
Michael Wyand | M | 68 |
Onebiopharma, Inc.
Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA. | - |
David Reese | M | 61 | 19 años | |
Todd Bazemore | M | 53 | 4 años | |
Biren Amin | M | 51 | 2 años | |
Anne Prener | M | 66 | 3 años | |
Søren Møller | M | 56 | 4 años | |
David Shapiro | M | 69 | 4 años | |
John W. Ford | M | - |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | 8 años |
Gary Whale | M | 50 | 1 años | |
Lamine Mbow | M | - | 3 años | |
Jonathan Freve | M | 46 | 4 años | |
Dave Brady | M | - | - | |
Marlyn Mathew | F | - | - | |
Harjit Singh | M | - | - | |
Morana Jovan-Embiricos | M | 57 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Anders Pedersen | M | 64 | 4 años | |
Theresa Lowry | F | 50 | - | |
Derek Miller | M | - | 21 años | |
Matt Roden | M | 53 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 1 años |
Gert-Jan Mulder | M | - |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | - |
Mike Zahigian | M | - | 23 años | |
Bobby G. Soni | M | 53 |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | - |
David Morris | M | - |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | - |
Alexander Mayweg | M | 49 |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | - |
Ciaran Lawlor | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 3 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Keith Leonard | M | 62 | 24 años | |
Preston Klassen | M | 55 | 12 años | |
Scott Rocklage | M | 69 | 3 años | |
Robert Clarke | M | 56 | 15 años | |
Garry Neil | M | 70 | 5 años | |
Tina Nova | M | 70 | 18 años | |
William Duke | M | 51 | 4 años | |
David W. Beier | M | 75 | 10 años | |
Michael Kelly | M | 67 | 14 años | |
Kathryn Falberg | F | 63 | 6 años | |
John Smither | M | 71 | 15 años | |
Dominic P. Behan | M | 59 | 19 años | |
J. Buchi | M | 69 |
EPIRUS Biopharmaceuticals, Inc. /Old/
EPIRUS Biopharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology EPIRUS Biopharmaceuticals, Inc. develops monoclonal antibodies. It offers pharmaceutical products. The company is headquartered in Boston, MA. | 3 años |
Craig M. Audet | M | 59 | 5 años | |
Susan Lundeen Smuck | F | 57 | 22 años | |
Jay Birnbaum | M | 79 | - | |
Michael Severino | M | 58 | 10 años | |
Sean E. Harper | M | 61 | 16 años | |
John Moriarty | M | 56 | 6 años | |
Vasant Prakash Gandhi | M | - | 5 años | |
Craig Shepherd | M | - | 7 años | |
Cynthia Patton | F | 62 | 15 años | |
James Daly | M | 63 | 9 años | |
Thomas Zindrick | M | 65 | 8 años | |
Willard Dere | M | 70 | 11 años | |
Cynthia Flowers | F | 64 | 5 años | |
Erin Lavelle | F | 46 | 15 años | |
Joan Schmidt | F | 60 | - | |
Leonard Schaeffer | M | 78 | 9 años | |
Christine Anna White | M | 72 | 12 años | |
Donald D. Belcher | M | 84 | 14 años | |
George Morrow | M | 72 | 10 años | |
Jerry D. Choate | M | 86 | - | |
Steven W. Spector | M | 59 | 19 años | |
Brian M. McNamee | M | 67 | - | |
Timothy Martin | M | 55 | 3 años | |
Dominique Monnet | M | 65 | 11 años | |
Robert Nelsen | M | 60 | 8 años | |
Martin Simonetti | M | 66 | 7 años | |
Anna Richo | F | 63 | - | |
Joseph Turner | M | 72 | 7 años | |
Randall E. Woods | M | 72 | 13 años | |
J. Reason | M | 83 | 12 años | |
Scott H. Bice | M | 81 | 15 años | |
Phillip Schneider | M | 67 | 11 años | |
Frank J. Biondi | M | 79 | 15 años | |
Rachel Lenington | F | 51 | 10 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 92 | 92.00% |
Reino Unido | 8 | 8.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Amit Munshi
- Red Personal